Principal Quality Assurance Validation Specialist
Regeneron Pharmaceuticals
Summary
At Regeneron, we use science and innovation to develop life-changing medicines for people with serious diseases. The Principal Quality Assurance Validation Specialist validates and qualifies equipment, systems, and processes in accordance with regulatory requirements and support, follow and implement company manufacturing standards policies and procedures.
Job description
Discover your role
- Generates, implements and/or reviews master and completed qualification and validation protocols, summary reports and associated data for conformance to regulations, SOPs, specifications and other applicable acceptance criteria
- Analyzes the results of testing and determines the acceptability of results against pre-determined criteria
- Investigates and troubleshoots problems which occur and determines solutions or recommendations for changes and/or improvements
- Reviews, edits and approves deviation notifications, deviation investigations, corrective actions, change controls, SOPs, reports and other documentation
- Coordinates with other departments or outside contractors/vendors to complete validation tasks
- May supervise, provide direction and assign work to Validations Specialists and/or contingent workers to meet goals and deadlines
- Manages projects and prepares status reports
- May present at both internal and external (regulatory) audits
- Other duties assigned by management
- Some travel may be required
This role requires
- BS/BA in Engineering, Chemistry, or Life Sciences
- 8+ years of relevant experience as a Principal Specialist
- Some supervisory and/or leadership experience preferred
Requirements
- BS/BA in Engineering, Chemistry, or Life Sciences
- 8+ years of relevant experience as a Principal Specialist
- Some supervisory and/or leadership experience preferred
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.